Using mRNA to Rethink Cardiovascular Therapy: A New Era in Precision Medicine
By Dr. Ajit Magadum, Assistant Professor, Center for Regenerative Medicine, Internal Medicine, USF Health Heart Institute, Tampa
Cardiovascular diseases (CVDs) remain the leading global cause of mortality, claiming over 20 million lives annually and imposing enormous healthcare costs, approximately $250 billion annually in direct healthcare expenses in the United States alone. Despite significant advancements in surgical techniques, pharmacological treatments, and medical devices, our current strategies still fall short in addressing the root molecular causes of cardiac dysfunction, particularly the irreversible damage and tissue loss following myocardial infarction (MI) and during heart failure (HF). In response, a growing body of research is shifting toward regenerative approaches that aim to promote cardiomyocyte proliferation, survival, and the reversal of adverse cardiac remodeling. Among the most promising avenues in this new therapeutic landscape is the development of modified messenger RNA (modRNA or mRNA) therapeutics—a technology with the potential to transform cardiovascular medicine.
The clinical success of mRNA vaccines during the COVID-19 pandemic propelled mRNA therapeutics from a novel concept into mainstream biotechnology. These vaccines demonstrated not only safety and efficacy but also the scalability and adaptability of synthetic mRNA as a platform. We are applying the same principles to develop transient, non-integrating, and customizable gene therapies for CVD. Unlike DNA-based therapies, which require nuclear entry and pose risks of genomic integration, mRNA operates within the cytoplasm, directly translating into therapeutic proteins. This characteristic offers a strategic advantage: it allows precise temporal control over gene expression, especially valuable during the acute phases of myocardial injury when rapid intervention can significantly improve clinical outcomes. Unlike traditional small-molecule or protein-based therapies that often provide symptomatic relief, mRNA therapeutics aim to address the underlying pathophysiological mechanisms of cardiac injury, such as cardiomyocyte death, inflammation, fibrosis, and impaired angiogenesis. mRNA therapies can be engineered to express pro-survival, pro-proliferative, pro-angiogenic, or anti-fibrotic factors directly in the ischemic myocardium, offering potential to repair and regenerate damaged heart tissue
In conclusion, mRNA therapeutics mark a transformative shift in cardiovascular medicine. By offering transient, precise, and programmable protein expression, mRNA-based therapies enable interventions that were previously unimaginable.
My research focuses on the design and delivery of modRNA or mRNA therapeutics to address both acute and chronic cardiac injury. We engineer synthetic mRNAs encoding key genes that enhance cardiomyocyte survival, promote angiogenesis, inhibit fibrosis, and reduce oxidative stress in the ischemic myocardium. These mRNAs incorporate advanced modifications, including optimized codon usage and nucleotides like N1-methylpseudouridine, to increase translational efficiency while minimizing innate immune responses. At the Icahn School of Medicine at Mount Sinai, Temple University, and currently at the USF Health Heart Institute in Tampa, I have screened, synthesized, and evaluated several promising therapeutic mRNAs—including PSAT1, PKM2, Lin28a, and Pip4k2c—for cardiovascular disease. Delivered in preclinical rodent models of MI, these mRNAs have shown efficacy in reducing apoptosis, promoting regeneration, and improving cardiac function, as measured by echocardiography and histopathological analysis.
mRNA therapeutics offer multiple intrinsic advantages that make them highly suitable for cardiovascular gene therapy. First, they are non-integrating and allow transient expression, minimizing long-term genetic risks while enabling repeat dosing, critical in cardiac tissues. Second, synthetic mRNA can be rapidly and scalably manufactured in vitro, allowing for fast iteration and mass production, as exemplified by the COVID-19 vaccine rollout. Third, mRNA sequences can be easily customized to encode virtually any therapeutic protein, including transcription factors, growth factors, and cell-cycle regulators. Fourth, through structural modifications and rigorous purification, modern mRNA formulations achieve reduced immunogenicity without compromising efficacy. Finally, with advances in lipid nanoparticle (LNP) delivery systems, we are now beginning to overcome the historical limitation of liver-centric delivery and are advancing methods to target extrahepatic tissues such as the heart.
Achieving efficient cardiac-specific delivery is one of the main technological problems in mRNA therapies for CVDs. The heart’s intrinsic properties, including its rapid blood flow, dense extracellular matrix, fibrotic environment following injury, and robust immune surveillance mechanisms, complicate targeted delivery. Our research has developed innovative solutions to these hurdles. One such approach is the development of SMRTs (Specific Modified RNA Translational switches), which harness cell-type-specific microRNA profiles to achieve cardiomyocyte-specific protein expression, ensuring that gene translation is confined to desired cardiac cell populations. This is a pioneering step in achieving precise spatial control over therapeutic action. Additionally, we have made substantial progress in optimizing LNP formulations, adjusting parameters such as particle size, surface charge, and lipid composition to enhance cardiac tropism and tissue retention. We are also exploring untranslated region (UTR) engineering to fine-tune the kinetics of mRNA translation and maximize therapeutic protein yield in target cells.
Looking forward, several key milestones will shape the future of mRNA therapeutics for cardiovascular disease. Achieving robust cardiac-specific targeting remains a top priority. Advances in delivery vehicle design, including LNPs with cardiotropic ligands and peptide conjugates, hold significant potential. Another challenge is regulating expression levels and half-life. New strategies that modulate mRNA degradation rates could reduce dosing frequency and enhance therapeutic sustainability. Translation from rodent models to large animals such as pigs, which more closely mirror human cardiovascular physiology, is currently underway. These large-animal studies are vital for bridging the gap to human clinical trials. Furthermore, regulatory and manufacturing pathways must be standardized to ensure consistent product quality, safety, and efficacy across batches. While the regulatory environment is rapidly adapting to accommodate mRNA-based innovations, establishing long-term safety data remains essential. These therapies could complement or even reduce the need for more invasive procedures such as mechanical support devices or heart transplantation, ultimately offering a precision medicine approach for patients with limited treatment options in ischemic heart disease and heart failure.
In conclusion, mRNA therapeutics mark a transformative shift in cardiovascular medicine. By offering transient, precise, and programmable protein expression, mRNA-based therapies enable interventions that were previously unimaginable. These therapies are not merely alternatives, they represent a fundamentally new modality in treating cardiac diseases. At the USF Health Heart Institute, we are working to move innovative technologies from the lab to the clinical setting. With continued innovation in delivery systems, collaborative networks, and forward-thinking regulatory policies, we are confident that mRNA therapeutics will become a cornerstone in the fight against cardiovascular disease. The future of precision medicine is here, and mRNA is leading the way.
Author Bio:
Dr. Ajit Magadum is an Assistant Professor at the Center for Regenerative Medicine, Internal Medicine, and USF Health Heart Institute, University of South Florida. His research focuses on therapeutic mRNA delivery for heart repair and regeneration, with a particular interest in non-viral gene therapy platforms.